Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Methods of Outcomes Measurement in Nail Psoriasis

Augustin M.a · Ogilvie A.b

Author affiliations

aCenter for Health Services Research in Dermatology (CVderm), Department of Dermatology, University Clinics of Hamburg, Hamburg, and bPsoriasis Clinic, Department of Dermatology, University Clinics of Erlangen, Erlangen, Germany

Related Articles for ""

Dermatology 2010;221(suppl 1):23–28

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 09, 2010
Issue release date: August 2010

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Nail involvement is a common feature of psoriasis, predicting higher disease severity and greater impairment in quality of life. Valid assessment of nail psoriasis is relevant for research and routine clinical use. However, no measurement standards have currently been developed. Objective: To identify state-of-the-art outcomes measurements in nail psoriasis by literature analysis. Methods: Systematic Web-based literature search, followed by structured critical appraisal and consecutive descriptive report. The search focused on methodological and epidemiological publications and papers describing outcomes of clinical trials on nail psoriasis. Results: Initially, 646 publications met the primary criteria. After non-relevant or replicate publications were excluded, 66 papers were analysed, including clinical trials or case reports (n = 41), reviews (n = 11) and methodological or epidemiological studies (n = 14). In total, 23 clinical outcomes measures and 15 patient-reported outcomes (PRO) tools were used. None had been validated according to recent standards. In the studies with clinical interventions (n = 41), NAPSI (Nail Psoriasis Severity Index; n = 4) or target NAPSI (n = 2) were the most often used single tools, followed by Physician’s Global Assessment (n = 3). However, in 16 studies, no specifically described outcomes measures were used. Conclusion: Valid clinical outcomes measures in nail psoriasis are rare. Existing tools lack validation and standardisation. A need exists for accurate and scientifically sound evaluation of nail psoriasis severity in trials and clinical practice. To cover all elements of nail psoriasis, the optimal nail psoriasis assessment tool would include both PRO and physician-assessed outcomes measures.

© 2010 S. Karger AG, Basel


References

  1. Schäfer I, Rustenbach SJ, Zimmer L, Augustin M: Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008;217:169–172.
  2. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M: Comorbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147–151.
  3. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermaology 2001;137:280–284.
  4. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter prospective cross-sectional study in Germany. Dermatology 2008;216:366–372.
  5. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982–986.
  6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–2673.
  7. Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008;35:1354–1358.
  8. Reich K, Krüger K, Mössner R, Augustin M: Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009;160:1040–1047.
  9. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M: Prevalence and clinical features of psoriatic arthritis and joint complaints in 2,009 patients with psoriais: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683–691.
  10. Sterry W, Strober BE, Menter A; on behalf of the International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649–655.
  11. Farber EM, Nall L: Nail psoriasis. Cutis 1992;50:174–178.
  12. Van Laborde S, Scher RK: Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. Dermatol Clin 2000;18:37–46.
  13. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA: Nail psoriasis in Germany: Epidemiology and burden of disease. Br J Dermatol 2010, Epub ahead of print.
  14. Rich P, Griffiths CEM, Reich K, Nestle FO, Scher RK, Li S, Xu S, Hsu MC, Guzzo C: Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224–231.
  15. Baran RL: A nail psoriasis severity index. Br J Dermatol 2004;150:568–569.
  16. Cannavò SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B: Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study. Dermatology 2003;206:153–156.
  17. Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C: Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010;24:22–27.
  18. Rich P, Scher RK: Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206–212.
  19. Lawry M: Biological therapy and nail psoriasis. Dermatol Ther 2007;20:60–67.
  20. Kacar N, Ergin S, Erdogan BS: The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol 2008;22:219–222.
  21. Cassell SE, Bieber JD, Rich P, Tutuncu ZN, Lee SJ, Kalunian KC, Wu CW, Kavanaugh A: The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123–129.
  22. Aktan S, Ilknur T, Akin C, Ozkan S: Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol 2007;32:141–144.
  23. Gupta AK, Cooper EA: Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009;13(suppl 2):S102–S106.
  24. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes, ed 2. Oxford, Oxford Medical Publications, 1997.
  25. Kerkmann U, Winkelman W, Wang Y, Reich K: Target nail NAPSI correlates with number of nails involved: a clinically efficient, useful, and precise assessment for nail psoriasis severity (poster). Presented at the 18th Congress of the European Academy of Dermatology and Venereology, 7–11 October 2009, Berlin, Germany, poster 1164.
  26. Augustin M, Amon U, Braathen L, Bullinger M, Gieler U, Klein GF, Schultz-Amling W: Assessment of quality of life in dermatology (German national guideline). J Dtsch Dermatol Ges 2004;9:802–806.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: August 09, 2010
Issue release date: August 2010

Number of Print Pages: 6
Number of Figures: 3
Number of Tables: 3

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.